Brief: Following Positive Phase 2A Pancreatic Cancer Data, Can-Fite Advances Namodenoson Into Phase 2B Combination Study With Immunotherapy
13/05/2026 12:01
Can Fite Biopharma Ltd CANF.TA: FOLLOWING POSITIVE PHASE 2A PANCREATIC CANCER DATA, CAN-FITE ADVANCES NAMODENOSON INTO PHASE 2B COMBINATION STUDY WITH IMMUNOTHERAPY CAN FITE BIOPHARMA LTD - TO ADVANCE NAMODENOSON INTO PHASE 2B PANCREATIC CANCER STUDY WITH IMMUNOTHERAPY Source text: ID:nGNXbvHWkg Further company coverage: CANF.TA
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage